2027 ASENT Annual Meeting Abstract Submissions (September 07, 2026)

Mon, 07 Sep 2026 04:00:00 GMT

Submitting Your Abstract to ASENT 2027

Deadline: October 30, 2026 at 11:59PM ET

The Abstract Review Committee is committed to presenting the best in neurotherapeutics research at the ASENT Annual Meeting. All abstracts are evaluated by experts in neurotherapeutics according to the following criteria and overall merit:

Scientific or clinical impact
Quality of data, analysis, and presentation
Relevance to the discovery and/or development of neurotherapeutics and inclusion of novel targets or new initiatives.
Abstracts must be submitted, presented, and cited in English.

The abstract should describe original research broadly relevant to the goal of ASENT, which is to encourage and advance the development of improved therapies for diseases and disorders of the nervous system. Please check your abstract carefully for typographical errors, misspellings, etc. Be sure to include data or results when available.

FAQs on Eligibility

ASENT welcomes encore abstracts, or those abstracts that have been previously presented at other recent scientific meetings, or submitted for consideration to other scientific meetings.
Trainees and early career researchers are highly encouraged to submit
All sectors (academic, industry, government, etc.) are welcome to submit
Trial designs or trials-in-progress are welcome and considered
Case studies or case reports will not be considered

If Accepted

One presenting author must be designated to attend the Annual Meeting in person. All attendees must register to attend the meeting via www.asent.org.

Poster Presentations

If your abstract is selected for a poster, you will need to be available to participate in our poster presentation at the annual meeting. This is scheduled to take place on Thursday, March 18th, 2027. Award winners for outstanding posters will be announced during the annual meeting.

Oral Presentations

Submitted abstracts that most closely conform to the above criteria may also be selected for a 10-minute oral presentation (including 2 minute Q&A) at our Oral Presentation session. ASENT encourages abstracts from privately or publicly-held startup companies, in addition to government or academic labs that conduct neurotherapeutics research.

About the Meeting

The ASENT Annual Meeting attracts a broad spectrum of researchers, clinicians, investors, and other leaders in neurotherapeutics from all over the world, across all neurologic disease areas. Oral presentations increase exposure to strategic partners in life sciences who have supported novel approaches through partnerships or strategic investments.

For questions regarding abstracts, please email aditya.joshi@pennmedicine.upenn.edu.

2027 ASENT Annual Meeting and Clinical Trials Course (March 15, 2027)

Mon, 15 Mar 2027 12:00:00 GMT

Neurotherapeutics Clinical Trials Course: March 15-16, 2027
ASENT 2026 Annual Meeting: March 17-19, 2027

The ASENT 2026 Annual Meeting and Clinical Trials Course, the premier neurotherapeutics conference will take place March 17-19, 2027 at the Hyatt Regency Bethesda in Bethesda, MD. This scientific meeting is where senior leaders from leading payers, providers, employers, investors, fast-growing startups, pharma, policymakers, funders and innovation centers gather with one central focus, improving the process of bringing neurotherapeutics to market.

Advance Program Submit an Abstract Register Clinical Trials Course Exhibit Opportunities

ASENT's popular Neurotherapeutic Clinical Trials Course runs March 15-16. Followed by the ASENT 2026 Annual Meeting, which runs March 17-19, all in one location.

Attendees interested in participating in both the Clinical Trials Course and Annual Meeting are encouraged to select the appropriate registration level and then add on the clinical trials course during the registration process for an additional $150.

The plenary sessions, panel discussions, outstanding pipeline presentations and poster sessions focus on the latest science in neurotherapeutics. The conference content will focus on the latest science in neurotherapeutics including innovations across disease states, novel delivery systems, gene therapy and biomarkers, and of course the latest drug therapies and devices. The event features plenary sessions, panel discussions, satellite luncheons, networking meetings, pipeline presentations and poster sessions.

WHO ATTENDS

American Society for Experimental Neurotherapeutics upcoming events